Erlotinib Recruiting Phase 3 Trials for Stage IV EGFR Mutated NSCL With Brain Metastases Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02882984Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)